Virtu Financial LLC Invests $568,000 in Solventum Co. (NYSE:SOLV)

Virtu Financial LLC purchased a new position in shares of Solventum Co. (NYSE:SOLV) in the third quarter, HoldingsChannel reports. The fund purchased 8,141 shares of the company’s stock, valued at approximately $568,000.

Several other hedge funds also recently made changes to their positions in the business. Deseret Mutual Benefit Administrators bought a new stake in shares of Solventum in the second quarter worth $25,000. Hollencrest Capital Management bought a new stake in Solventum during the 2nd quarter worth about $25,000. Richard W. Paul & Associates LLC bought a new stake in Solventum during the 2nd quarter worth about $26,000. Family Firm Inc. acquired a new position in shares of Solventum during the 2nd quarter worth about $26,000. Finally, Copeland Capital Management LLC acquired a new stake in shares of Solventum in the third quarter valued at about $26,000.

Solventum Stock Down 0.6 %

NYSE:SOLV opened at $69.56 on Friday. The firm’s fifty day moving average price is $70.91 and its two-hundred day moving average price is $63.22. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on SOLV shares. Morgan Stanley raised their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Stifel Nicolaus started coverage on shares of Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. BTIG Research assumed coverage on shares of Solventum in a research report on Thursday, September 5th. They set a “neutral” rating on the stock. Mizuho started coverage on shares of Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. Finally, Wolfe Research assumed coverage on shares of Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.